Multicenter study shows venetoclax increases progression-free survival in intermediate-risk AML, indicating genotype-based approaches.
Key Points
This study aims to compare the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy in intermediate-risk AML patients.
Multicenter retrospective analysis of newly diagnosed intermediate-risk AML patients
Comparison of treatment outcomes between venetoclax/hypomethylating agents and intensive chemotherapy
Evaluation of complete remission rates, transfusion needs, and infection rates
Venetoclax/hypomethylating agents achieved a 75.3% complete remission rate compared to 63.4% for intensive chemotherapy
Patients with dnmt3a mutations showed a favorable response to venetoclax
Venetoclax significantly improved 3-year overall survival and progression-free survival in untreated patients without transplant